RxDoctor Payments Data

Arumugam Sivakumar, MD

Gastroenterology · Henderson, NVNPI 1578563102

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,504 of the $7,252 with a category attached, or 89.7%. 22 manufacturers reported payments, led by Johnson & Johnson at 35.3% of the total.

$7,252in general payments, 2019–2025

Across 389 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$568
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$530
  • Phathom Pharmaceuticals, Inc.$337
  • Braintree Laboratories, Inc.$263
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$6,50490%
  • Education$5147%
  • Gifts$2353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,252 in reported general payments places this provider in the 70th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada

Medicare billing

Part B allowed, 2024
$116,578
Medicare patients
427
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase25$53,920
ZenpepLipase/Protease/Amylase12$35,423
LinzessLinaclotide24$23,073
Mesalamine13$6,498
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C37$5,260
Dexlansoprazole DrDexlansoprazole15$2,908
Pantoprazole Sodium227$2,678
Lansoprazole47$1,620
Famotidine124$1,155
Budesonide DrBudesonide12$1,091
Omeprazole83$569
Dicyclomine Hcl31$440
Ondansetron OdtOndansetron17$436
Esomeprazole Magnesium14$296
Hydrocortisone12$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,479$76,99349 claims
Aimmune Therapeutics, Inc.Zenpep$45$35,42312 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$530$5,26037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →